March 5, 2020
Ono Pharmaceutical said on March 4 that it has filed its combo therapy pairing the BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib) for an additional indication of certain colorectal cancer together with Merck Biopharma’s Erbitux (cetuximab). The triplet...read more